How the Terminal Disclaimer Went from Limiting Monopolies to Blocking Generics

In the 1960s, federal courts turned to terminal disclaimers to keep patent holders from using follow-on patents to extend a monopoly beyond its original term. Today, that same tool reduces competition in the pharmaceutical sector by increasing the number of patents a company must challenge to manufacture a lower-cost generic version of a traditional small-molecule...